With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.234109-20-7,Methyl 6-oxopiperazine-2-carboxylate,as a common compound, the synthetic route is as follows.
EXAMPLE 55 5-Oxo-piperazine-1,3(R or S)-dicarboxylic acid 1-benzyl ester 3-methyl ester. N,N-Dimethylaminopyridine (0.43 g, 3.5 mmol) and benzylchloroformate (0.55 g, 3.8 mmol) are added to a solution of methyl 6-oxopiperazine-2-carboxylate (0.50 g, 3.2 mmol) (Aebischer, B., Helv. Chim. Acta 1989, 72, 1043-1051) in CH2Cl2 at RT. After 1 h, the reaction mixture is poured into EtOAc and washed with saturated NaHCO3 and brine then dried over MgSO4, filtered and concentrated to dryness to give a solid (0.90 g, 3.1 mmol) which is used in subsequent reactions without further purification. 1H NMR (CDCl l3, 300 MHz) delta7.40 (bs, 5H), 6.32 (bs, 1H), 5.15 (s, 2H), 4.00-4.30 (m, 3H), 4.23 (s, 3H), 3.70-3.80 (m, 2H). MS (EI) m/z 292 (M+)., 234109-20-7
As the paragraph descriping shows that 234109-20-7 is playing an increasingly important role.
Reference£º
Patent; AVENTIS PHARMACEUTICALS INC.; US2004/102450; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics